News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,790 Results
Type
Article (41436)
Company Profile (291)
Press Release (655063)
Section
Business (209599)
Career Advice (2057)
Deals (36552)
Drug Delivery (88)
Drug Development (82530)
Employer Resources (170)
FDA (16358)
Job Trends (15325)
News (354190)
Policy (33776)
Tag
Academia (2572)
Africa (773)
Alliances (50915)
Alzheimer's disease (1150)
Approvals (16307)
Arizona (176)
Artificial intelligence (74)
Asia (39559)
Australia (6302)
Bankruptcy (360)
Best Places to Work (11344)
Biosimilars (64)
Biotechnology (185)
C2C Services and Suppliers (79734)
California (1504)
Canada (827)
Cancer (329)
Career advice (1719)
Cell therapy (99)
China (111)
Clinical research (64413)
Collaboration (105)
Colorado (64)
Connecticut (61)
COVID-19 (2541)
Cystic fibrosis (73)
Data (121)
Diabetes (64)
Diagnostics (6020)
Drug pricing (66)
Earnings (85321)
Employer resources (143)
Europe (83978)
Events (110122)
Executive appointments (89)
FDA (16524)
Florida (206)
Funding (92)
Gene therapy (82)
GLP-1 (523)
Government (4397)
Healthcare (18743)
Hotbed/Location (489872)
Idaho (56)
Illinois (235)
Indiana (138)
Infectious disease (2565)
Inflammatory bowel disease (90)
Interviews (316)
IPO (16439)
Job creations (4044)
Job search strategy (1481)
Kansas (93)
Layoffs (407)
Legal (8288)
Lung cancer (70)
Manufacturing (76)
Maryland (337)
Massachusetts (1288)
Medical device (13095)
Medtech (13098)
Mergers & acquisitions (19907)
Metabolic disorders (220)
Michigan (115)
Minnesota (201)
Neuroscience (1265)
New Jersey (475)
New York (479)
NextGen Class of 2024 (6601)
Non-profit (4500)
North Carolina (568)
Northern California (683)
Obesity (136)
Ohio (96)
Opinion (189)
Patents (56)
Pennsylvania (512)
People (57640)
Pharmaceutical (84)
Phase I (19873)
Phase II (28347)
Phase III (21311)
Pipeline (89)
Postmarket research (2634)
Preclinical (8477)
Press Release (68)
Rare diseases (114)
Real estate (6227)
Recruiting (65)
Regulatory (21953)
Research institute (2349)
Resumes & cover letters (354)
South America (1150)
Southern California (609)
Startups (3704)
Texas (181)
United States (7311)
Vaccines (461)
Washington State (232)
Weight loss (122)
Date
Today (68)
Last 7 days (470)
Last 30 days (2464)
Last 365 days (38154)
2024 (24752)
2023 (40629)
2022 (51798)
2021 (56332)
2020 (54795)
2019 (47402)
2018 (35773)
2017 (33139)
2016 (32667)
2015 (38631)
2014 (32540)
2013 (27657)
2012 (29748)
2011 (30497)
2010 (28504)
696,790 Results for "arrowhead pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events.
May 31, 2024
·
5 min read
Drug Development
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN.
June 25, 2024
·
12 min read
Biotech Beach
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events.
April 29, 2024
·
6 min read
Business
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
Arrowhead Pharmaceuticals, Inc. announced financial results for its fiscal 2024 second quarter ended March 31, 2024.
May 9, 2024
·
10 min read
Biotech Beach
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
Arrowhead Pharmaceuticals, Inc. announced a $50 million milestone payment was received from Royalty Pharma plc.
May 2, 2024
·
6 min read
Drug Development
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
Arrowhead Pharmaceuticals, Inc. announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran in patients with mixed hyperlipidemia.
May 28, 2024
·
10 min read
Drug Development
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
Arrowhead Pharmaceuticals, Inc. announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran in patients with mixed hyperlipidemia.
May 29, 2024
·
9 min read
Biotech Beach
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually.
June 24, 2024
·
6 min read
Biotech Beach
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
Arrowhead Pharmaceuticals, Inc. announced that it is scheduled to participate in the following upcoming events.
March 4, 2024
·
4 min read
Business
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024.
April 24, 2024
·
4 min read
1 of 69,679
Next
